Clinical Trials Browser

Phase 2/3 × OTHER_GOV × Bevacizumab × Clear all

NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

Uterine Cervical Neoplasms

NCT07293468 2025-12-19

BIIRTH

Phase 2/3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT00450203 2016-12-01

ST03

Phase 2/3 Unknown

Gastrointestinal

Oesophagogastric Cancer